1 / 15

SAAVI: Advancing HIV Vaccine Research in Southern Africa

Established in late 1999, SAAVI aims to develop an affordable, effective, and locally relevant preventative HIV vaccine for Southern Africa. The organization conducts scientific and clinical research, collaborates with ethics committees, and engages in regulatory processes. With a focus on HIV genetic diversity, immunology assessments, animal and human trials, and advocacy, SAAVI navigates challenges in vaccine development and community involvement. The organization also addresses ethical considerations and secures funding for clinical trials and manufacturing. Through strategic alliances and a commitment to excellence, SAAVI aims to make significant progress in the fight against HIV/AIDS.

oliana
Download Presentation

SAAVI: Advancing HIV Vaccine Research in Southern Africa

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Established in late 1999 • Scientific/clinical resources • Ethics committees • Regulatory body TT - 2002

  2. SAAVIaims to develop anaffordable, effective and locally relevantpreventativeHIV vaccineforsouthern Africa

  3. G G J J AE G AE H AE AG AG B B B AG B B A B A B A A D D C D C D D C C C F C F K C K C C C C C C C C C C HIV genetic diversity C. Williamson et al

  4. Immunology assessment Animal Human Making the vaccine Testing the vaccine Others Advocacy & community Ethical issues TT - 2002

  5. What do we expect from an HIV vaccine?

  6. 90% Progress to AIDS in 5 years 5% “Viral load” in HIV Amount of HIV

  7. Potential end-points of HIV-vaccine efficacy trials

  8. SAAVI Challenges TT - 2002

  9. Immunology assessment Animal Human Making the vaccine Testing the vaccine Others Advocacy & community Ethical issues TT - 2002

  10. Supporters and Funds TT - 2002

  11. Good vaccine candidates • HIV subtypes • Community involvement • Ethical studies • Access to product • Pricing • Technology transfer Appropriate Clinical Trials $30 million TT - 2002

  12. Product? • When? • What dose? • Manufacturing plant • Personnel • Dose price • Distribution capacity Manufacturing • Clinical trials lot • Bulk supply $350 million TT - 2002

  13. Government • Medicines Control Council • Ethics committees • Medical aids • Life Insurance • Blood transfusion services • State Vaccine Institute Strategic national alliances TT - 2002

  14. Strategic international alliances • NIH • HVTN • IAVI • AAVP • EU • Public / private TT - 2002

  15. CONCLUSIONS • SAAVI has dynamic team • Different to all other initiatives • Committed to excellence • Massive / maturing challenges • Consolidate and expand TT - 2002

More Related